Imatinib
Primary Peritoneal Cancer
Henry M. Jackson Foundation for the Advancement of Military MedicineSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
154 Active assets in the Primary Peritoneal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II GOG Foundation | Phase 3 | BBB |
Carboplatin University of Washington | Phase 3 | BBB |
Inno-206 Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | BBB |
Hycamtin Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | BBB |
PEGFILGRASTIM TORL Biotherapeutics, LLC | Phase 2/3 | BBB |
View all 50 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →